IGF ligand neutralizing antibodies are good candidates due to the lack of side effects, such as hyperinsulinemia and hyperglycemia, and may be combined with EGFR family inhibitors, Cyclin-dependent kinase (CDK) inhibitors, endocrine therapy or immune checkpoint inhibitors [39]. The gene discussed is IGF1; the disease is Hyperglycemia.